Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 29.66% year-over-year to $1.1 billion, compared with a TTM value of $4.0 billion through Dec 2025, up 35.61%, and an annual FY2025 reading of $1.1 billion, up 29.66% over the prior year.
  • Liabilities and Shareholders Equity was $1.1 billion for Q4 2025 at Catalyst Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2025 and bottomed at $209.1 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $651.9 million, with a median of $676.5 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity increased 23.62% in 2021, then skyrocketed 86.83% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $237.8 million in 2021, then skyrocketed by 57.97% to $375.6 million in 2022, then rose by 25.15% to $470.1 million in 2023, then surged by 81.11% to $851.4 million in 2024, then rose by 29.66% to $1.1 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CPRX at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $971.9 million in Q2 2025.